[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:digestive-system-neuroendocrine-tumor:somatostatin-receptor":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Digestive System Neuroendocrine Tumor","Somatostatin Receptor",12,[8,16,23,30,36,43,50,56,62,68,74,80],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05477576","Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy",[12],"Phase 3","RECRUITING","2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.713577Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04086485","Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:09.641312Z","2026-05-05T02:43:29.651483Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07150546","Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.",[27],"Phase 1","2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.200887Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT04609592","Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",[27],"2026-08-03T01:59:18.089574Z","2026-05-05T02:43:28.703397Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",[40],"Phase 4","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.860078Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":48,"content_modified":49},"NCT05773274","Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial",[47],"Phase 2","2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.798127Z",{"nct_id":51,"title":52,"phases":53,"status":13,"updated_at":54,"content_modified":55},"NCT06784752","Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:35:31.867759Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06427798","Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma\u002FParaganglioma Previously Treated With Systemic Targeted Radioligand Therapy",[20],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.752853Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT07165132","Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.",[27],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.257230Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors",[20],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.808808Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers",[27],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.023362Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.233960Z"]